Oncology Breakthrough: Investigating T-DXd in Breast Cancer Treatment
Investigating the Role of T-DXd in Breast Cancer Treatment
Cancer treatment advancements highlight T-DXd's promise in oncology, specifically for breast cancer. Dr. Sarah Sammons, a medical oncologist at Dana-Farber Cancer Institute, emphasizes the need for further research into trastuzumab deruxtecan (Enhertu; T-DXd) and its effectiveness for patients with low HER2 expression and brain metastasis.
Key Findings from the DESTINY-Breast03 Trial
In a recent interview, Dr. Sammons discussed key findings from the analysis of the DESTINY-Breast03 trial (NCT03529110). She pointed out a small amount of data currently available on HER2-low brain metastasis. Initial results indicate a promising 25% intracranial response rate in patients with brain metastasis assessed retrospectively from the DESTINY-Breast04 clinical trial (NCT03734029).
Future Research Directions
The promising results for T-DXd raise important questions regarding its application not only in breast cancer but also in other solid tumors that express HER2. With T-DXd recently approved for various solid tumors overexpressing HER2, there is excitement surrounding its potential for treating brain metastasis across different cancer types.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.